For patients with newly diagnosed multiple myeloma, induction treatment with a combination of bortezomib, doxorubicin, and dexamethasone followed by bortezomib maintenance therapy improves complete response, progression-free survival, and overall survival rates, according to a study published online July 16 in the Journal of Clinical Oncology.
JUMP
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment